These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29577029)

  • 1. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study.
    Hu P; Shang J; Zhang W; Gong G; Li Y; Chen X; Jiang J; Xie Q; Dou X; Sun Y; Li Y; Liu Y; Liu G; Mao D; Chi X; Tang H; Li X; Xie Y; Chen X; Jiang J; Zhao P; Hou J; Gao Z; Fan H; Ding J; Zhang D; Ren H
    J Clin Transl Hepatol; 2018 Mar; 6(1):25-34. PubMed ID: 29577029
    [No Abstract]   [Full Text] [Related]  

  • 2. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
    Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
    Farag MS; van Campenhout MJH; Sonneveld MJ; Fung S; van Erpecum KJ; Wong DK; Verhey E; de Man R; De Knegt RJ; Brouwer JT; Baak HC; Feld JJ; Liem KS; Boonstra A; Hansen BE; Janssen HLA
    J Viral Hepat; 2024 Apr; 31(4):197-207. PubMed ID: 38243144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial.
    Woo HY; Heo J; Tak WY; Lee HJ; Chung WJ; Park JG; Park SY; Park YJ; Lee YR; Hwang JS; Kweon YO
    PLoS One; 2022; 17(7):e0270716. PubMed ID: 35867702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M
    Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study.
    Liu Y; Li W; Jia T; Peng D; Li H; Li X; Lv S
    J Clin Transl Hepatol; 2018 Mar; 6(1):18-24. PubMed ID: 29577028
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
    Chan HLY; Chan FWS; Hui AJ; Li MKK; Chan KH; Wong GLH; Loo CK; Chim AML; Tse CH; Wong VWS
    J Viral Hepat; 2019 Jan; 26(1):126-135. PubMed ID: 30187604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients.
    Erken R; Loukachov VV; de Niet A; Jansen L; Stelma F; Helder JT; Peters MW; Zaaijer HL; Kootstra NA; Willemse SB; Reesink HW
    J Clin Exp Hepatol; 2022; 12(3):735-744. PubMed ID: 35677522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
    Kittner JM; Sprinzl MF; Grambihler A; Weinmann A; Schattenberg JM; Galle PR; Schuchmann M
    J Clin Virol; 2012 May; 54(1):93-5. PubMed ID: 22365367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
    Huang ZL; Zhao ZX; Deng H; Zhang YF; Lu CR; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
    Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.